Entering text into the input field will update the search result below

Anthera to terminate development of Sollpura after failed late-stage study

  • Nano cap Anthera Pharmaceuticals (OTC:ANTH) is set for an ugly day after announcing that lead candidate Sollpura failed to demonstrate non-inferiority to Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceuticals' PANCREAZE (pancrelipase) in a Phase 3 study.
  • The study, RESULT, failed to achieve the primary endpoint of an improvement in coefficient of fat absorption (CFA) from baseline within the 95% non-inferiority margin.
  • The study did achieve the secondary endpoint of coefficient of nitrogen absorption (CNA).
  • The company says it will terminate further development.
  • Shares, currently halted, will resume trading at 8:30 am ET.
  • Management will host a conference call at 8:30 am ET to discuss the results.

This was corrected on 02/06/2019 at 10:26 AM. Secondary endpoint met.

Recommended For You

About ANTH Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ANTH--
Anthera Pharmaceuticals, Inc.